Ninerafaxstat

Ninerafaxstat
Clinical data
Other names	IMB-1018972; IMB-101
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 2-[4-[(2,3,4-Trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate;
CAS Number	2254741-41-6;
PubChem CID	137359209;
ChemSpider	115007142;
UNII	0RB6V4E5XN;
ChEMBL	ChEMBL5095242;
Chemical and physical data
Formula	C22H29N3O5
Molar mass	415.490 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=C(C(=C(C=C1)CN2CCN(CC2)CCOC(=O)C3=CN=CC=C3)OC)OC;
	InChI InChI=1S/C22H29N3O5/c1-27-19-7-6-18(20(28-2)21(19)29-3)16-25-11-9-24(10-12-25)13-14-30-22(26)17-5-4-8-23-15-17/h4-8,15H,9-14,16H2,1-3H3; Key:AGVJLPKGBKSLKF-UHFFFAOYSA-N;

Ninerafaxstat^[1] (IMB-1018972 or IMB-101) is a cardiac mitotrope agent investigated by Imbria for diabetic cardiomyopathy,^[2] myocardial ischemia, and hypertrophic cardiomyopathy.^[3]

References[edit]

^ "Ninerafaxstat". pubchem.ncbi.nlm.nih.gov. Retrieved 4 December 2023.
^ Hundertmark, M; Siu, A G; Matthews, V; Lewis, A J; Grist, J T; Patel, J; Chamberlin, P; Sarwar, R; Yavari, A; Frenneaux, M P; Valkovic, L; Miller, J J J J; Neubauer, S; Tyler, D J; Rider, O J (3 October 2022). "A phase 2a trial investigating ninerafaxstat – a novel cardiac mitotrope for the treatment of diabetic cardiomyopathy (IMPROVE-DiCE)". European Heart Journal. 43 (Supplement_2). doi:10.1093/eurheartj/ehac544.246.
^ Chamberlin, Paul; Barrett, Lisa; Buckley, Neil; Mooney, George; Tremaine, Larry; van de Wetering, Jeroen; van Iersel, Thijs; Patel, Jai (May 2021). "Phase 1 Safety and Tolerability Study of Imb-1018972, A Novel Oral Modulator of Myocardial Substrate Utilization Designed to Improve Cardiac Metabolic Efficiency and Bioenergetics". Journal of the American College of Cardiology. 77 (18): 180. doi:10.1016/S0735-1097(21)01539-4. S2CID 235584926.